BSH 2022 | Current and future treatment approaches for HR-MDS
In this video, Pramila Krishnamurthy, MD, King’s College Hospital NHS Foundation Trust, London, UK, discusses the treatment of high-risk myelodysplastic syndromes (HR-MDS), drawing focus on the promise of novel agents. Dr Krishnamurthy first discusses the efficacy of combining venetoclax with azacitidine, which has shown great promise for the treatment of HR-MDS. Following this, Dr Krishnamurthy explains how novel immune therapies, such as the combination of magrolimab and azacitidine, are allowing patients with poor-risk mutational profiles to get to transplant, which is the ultimate goal of HR-MDS therapy. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
Disclosures
Ad board- Jazz
Honorarium- Astellas, Jazz
